Dr Reddys Laboratories RDY Estimates

NYSE RDY
$11.85 -0.03 (-0.25%)
As of: Sep 9, 2026 · 12:01 PM EDT
Analyst Estimates

Dr Reddys Laboratories Ltd Revenue Estimates

Periods 23
Next Period Q2 26
Consensus 796.87 M

Analysts expect Dr Reddys Laboratories Ltd to report revenue of 796.87 M for Q2 26, against a range of 764.34 M to 829.40 M. The most recent reported quarter, Q1 26, came in at 835.68 M, a 3.8% beat against the 805.00 M consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 951.11 M969.62 M996.16 M988.91 M1.00 B951.64 M785.89 M835.68 M--------
High Estimate 1.03 B980.48 M970.93 M1.04 B1.09 B892.81 M1.01 B863.25 M829.40 M902.66 M972.67 M1.03 B914.68 M955.84 M966.90 M1.18 B
Low Estimate 862.64 M876.32 M850.14 M895.93 M997.18 M837.75 M880.90 M746.75 M764.34 M842.46 M821.04 M943.27 M810.83 M796.72 M856.39 M990.63 M
Consensus Estimate 944.15 M928.40 M910.53 M965.52 M1.04 B865.28 M944.96 M805.00 M796.87 M872.56 M896.86 M988.55 M862.75 M876.28 M911.64 M1.08 B
Analyst Estimates

Dr Reddys Laboratories Ltd Earnings Per Share (EPS) Estimates

Periods 23
Next Period Q2 26
Consensus 0.10

Analysts expect Dr Reddys Laboratories Ltd to report earnings per share of 0.10 for Q2 26, against a range of 0.09 to 0.11. The most recent reported quarter, Q1 26, came in at 0.06, a 40.0% miss against the 0.10 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29
Reported (Actual) 0.180.200.220.200.200.160.030.06--------
High Estimate 0.210.220.240.210.200.170.120.110.110.120.140.130.140.160.160.18
Low Estimate 0.190.180.200.190.180.150.100.090.090.100.120.110.120.140.160.16
Consensus Estimate 0.200.200.220.200.190.160.110.100.100.110.130.120.130.150.160.17